Management ChangeJul 27, 2026, 06:01 AM
Legend Biotech CEO Ying Huang Steps Down; Alan Bash Appointed Interim CEO
AI Summary
Legend Biotech announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and from the Board of Directors, effective July 24, 2026. He will remain as an advisor through August to ensure a smooth transition. Alan Bash, current President of the CARVYKTI Business Unit, has been appointed Interim Chief Executive Officer. The Board has initiated a comprehensive search for a permanent successor, expressing confidence in Mr. Bash's ability to maintain continuity and execution.
Key Highlights
- Ying Huang, Ph.D., stepped down as CEO and Board member, effective July 24, 2026.
- Dr. Huang will serve as an advisor through August to support a smooth transition.
- Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer.
- The Board has initiated a comprehensive search process for a permanent successor.
- Frank Zhang, Chairman, thanked Dr. Huang for his 7 years of leadership and contributions.
- Legend Biotech is a global leader in cell therapy with over 3,000 employees.
Price Impact
More from LEGN